Darshan Eye Clinic and Surgical Centre, Chennai, Tamil Nadu, India.
Indian J Ophthalmol. 2013 Aug;61(8):420-1. doi: 10.4103/0301-4738.116071.
Keratoconus is a common ectatic disorder occurring in more than 1 in 1,000 individuals. The condition typically starts in adolescence and early adulthood. It is a disease with an uncertain cause and its progression is unpredictable, but in extreme cases, vision deteriorates and can require corneal transplant surgery. Corneal collagen cross-linking (CCL) with riboflavin (C3R) is a recent treatment option that can enhance the rigidity of the cornea and prevent disease progression. Since its inception, the procedure has evolved with newer instrumentation, surgical techniques, and is also now performed for expanded indications other than keratoconus. With increasing experience, newer guidelines regarding optimization of patient selection, the spectrum of complications and their management, and combination procedures are being described. This article in conjunction with the others in this issue, will try and explore the uses of collagen cross-linking (CXL) in its current form.
圆锥角膜是一种常见的扩张性疾病，发病率超过每 1000 人中 1 例。该病通常始于青少年和成年早期。其病因不明，病情进展不可预测，但在极端情况下，视力会恶化，可能需要进行角膜移植手术。角膜胶原交联（CXL）联合核黄素（C3R）是一种新的治疗选择，可增强角膜硬度，阻止疾病进展。自问世以来，该手术随着新型仪器、手术技术的发展而不断演变，目前已扩展到除圆锥角膜以外的适应证。随着经验的增加，关于优化患者选择、并发症谱及其管理以及联合手术的新指南正在不断描述。本文与本期刊登的其他文章一起，将尝试探讨目前形式的胶原交联（CXL）的应用。
